La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Evoke Pharma Bilan de santé

Santé financière contrôle des critères 5/6

Evoke Pharma possède un total de capitaux propres de $2.7M et une dette totale de $5.0M, ce qui porte son ratio d'endettement à 187.6%. Son actif total et son passif total sont $12.1M et de $9.5M.

Informations clés

187.6%

Ratio d'endettement

US$5.00m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$9.18m
Fonds propres	US$2.66m
Total du passif	US$9.47m
Total des actifs	US$12.14m

Mises à jour récentes de la santé financière

Recent updates

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14

Evoke Pharma shares surge on positive findings from Gimoti market research study

Jan 13

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de EVOK ( $12.1M ) dépassent ses passifs à court terme ( $9.5M ).

Passif à long terme: EVOK n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: EVOK dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de EVOK est passé de 0% à 187.6% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: EVOK dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: EVOK dispose d'une marge de trésorerie suffisante pour 1.5 ans si le flux de trésorerie disponible continue de croître à un taux historique de 0.9 % chaque année.

Evoke Pharma Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Recent updates

New major risk - Share price stability

Consensus revenue estimates fall by 17%

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.08 loss, revenue downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Consensus EPS estimates fall by 13%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 57%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Price target decreased to US$7.00

Consensus revenue estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Evoke to get US patent for nasal spray Gimoti

Consensus revenue estimates fall by 19%

Price target decreased to US$63.50

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Price target decreased to US$6.50

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

Consensus EPS estimates fall by 29%

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$9.50

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Price target increased to US$9.50

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$1.28m

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma announces positive findings from second GIMOTI market research study

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book